Open access
Aug 2026
Noncovalent SARS-CoV-2 main protease inhibitors targeting the catalytic dyad and primed substrate binding subsites
This study provides binding details for the designed compounds and demonstrates the feasibility of the joint X-ray/neutron structure-assisted drug design approach to generate more potent noncovalent nonpeptidic SARS-CoV-2 MPro inhibitors.
Dipendra Bhandari, Katerina Kovalevskaya, L. Coates et al.
· RSC Medicinal Chemistry · 0 citations